The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.
1) Client Situation
The client operated within the therapeutics-focused biotech ecosystem and required support with Biotech Data Platform And Governance in the context of Biotechnology. Leaders across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators sought a FAIR (Findable, Accessible, Interoperable, Reusable), GxP-compliant data platform with ontologies and master data to unify preclinical, CMC, clinical, and commercial datasets for analytics, interoperability, and data integrity. The diagnostic surfaced concrete pain points:
- Fragmented systems and siloed data
- Preclinical and discovery data spread across ELNs and file shares (omics, assays, plate reader outputs) without harmonized metadata; limited provenance and versioning.
- CMC/Tech Ops data fragmented across LIMS, MES/eBR, historian (batch parameters), QC/QA test results, deviation/CAPA, and stability databases; no consistent lot genealogy or ALCOA+ lineage to support investigations or comparability.
- Clinical operations data isolated across CTMS, EDC, eTMF, IxRS/IRT; no single subject/token linking eSource or lab results; limited SDTM/ADaM standardization, and slow biostats handoffs.
- Commercial data scattered across CRM (HCP/HCO), specialty pharmacy/distributor feeds, HUB/benefits verification, GTN/chargebacks, and market access systems; no golden HCP/HCO/account master.
- Data integrity and compliance risk
- Part 11/Annex 11 controls implemented inconsistently; audit trail coverage gaps for critical pipelines; CSV/CSA evidence not aligned to a risk-based validation approach.
- Lack of robust lineage and e-signature evidence; difficulty reconstructing data transformations for submissions and inspections.
- Inconsistent ontologies and master data
- No enterprise data model for subjects, sites, lots, assays, materials, HCP/HCOs, or products; conflicting identifiers across systems create discordant metrics and reconciliation overhead.
- Incompatible standards (CDISC, BioPAX, OBO Foundry ontologies, HL7 FHIR/IDMP) applied sporadically; no semantic layer for cross-domain analytics.
- Slow, brittle integrations and manual reconciliations
- Point-to-point ETLs and spreadsheets dominate; lack of data contracts; frequent schema breaks; operational dashboards require manual compilation each month/quarter.
- Latency: batch release and stability insights not visible to supply planners; enrollment and protocol deviations slow to propagate to finance/FP&A or safety teams.
- Privacy and patient data handling uncertainty
- HIPAA/GDPR de-identification/pseudonymization policies unclear; tokenization across clinical, safety, and real-world data not standardized; limited differential access (RBAC/ABAC) and consent management.
- Analytics limited by poor data readiness
- ML/AI pilots (e.g., yield prediction, patient-finding, signal detection) stagnate due to missing feature lineage, ungoverned training data, and lack of model risk management in GxP contexts.
- Governance gaps
- No enterprise data council or data stewardship; unclear ownership for critical domains; no DQ (data quality) KPIs; no catalog or business glossary; change management ad hoc.
Observed symptoms included: inspection observations tied to data integrity; prolonged deviation investigations due to missing genealogy; rework of SDTM/ADaM packages; redundant HCP/HCO records and conflicting account hierarchies; inability to calculate end-to-end metrics (e.g., lot release cycle time, time-to-therapy) with confidence; prolonged integration lead times for partner data; and leadership fatigue with dashboard inconsistency and late decision-making.
2) Project Objective
The primary objective focused on architecting and implementing a FAIR, GxP-compliant data platform and governance operating model—standardized ontologies, master data, risk-based validation, and secure integrations—that unified preclinical, CMC, clinical, and commercial data for reliable analytics, interoperability, and inspection-ready data integrity.
Secondary objectives included:
- Defining an enterprise data model and ontologies aligned to industry standards (CDISC SDTM/ADaM, BioPAX/OBO, HL7 FHIR, ISO IDMP) and business semantics for assays, materials, lots, batches, subjects, sites, products, HCP/HCO, and payers.
- Standing up master data and reference data management (MDM/RDM) for core entities (Item/Lot/COA, Site/Supplier, Subject/Token, HCP/HCO, Account) with stewardship and data quality rules.
- Designing a cloud-native, validated lakehouse/platform (catalog, lineage, metadata, security, data contracts) integrating ELN/LIMS/MES/eBR/eQMS, CTMS/EDC/eTMF/IRT, ERP/CRM/HUB/SP/SD feeds, and historian.
- Implementing risk-based CSV/CSA and Part 11/Annex 11 controls for GxP-relevant pipelines (audit trails, e-signature, access, backup/restore, change control) and appropriate “fit-for-purpose” controls for non-GxP data.
- Establishing privacy-by-design: de-identification/tokenization services, consent/provenance, RBAC/ABAC; HIPAA/GDPR compliance and data minimization.
- Enabling cross-domain analytics and ML/AI with MLOps, model governance, and feature lineage to support validated and non-validated use cases.
- Launching a data governance operating model (councils, stewards, business glossary, DQ KPIs) and change management to drive adoption.
3) Methodology and Approach
Workstream 1: Vision, Use Cases, and Target-State Design
We defined business-critical outcomes and the target architecture with cross-functional stakeholders (R&D, CMC/Tech Ops, Clinical, Safety/Pharmacovigilance, Commercial, QA/CSV, Security/Privacy, IT/Data).
- Use case portfolio:
- Preclinical: assay harmonization, sequence/omics lineage, compound/variant traceability, experiment reproducibility.
- CMC/Tech Ops: lot genealogy across DS/DP/packaging; deviation/CAPA analytics; yield/cycle time dashboards; stability trending; comparability and PPQ evidence readiness.
- Clinical: SDTM/ADaM standardization; protocol deviation signal detection; enrollment and site performance dashboards; PV signal triage.
- Commercial: GTN analytics, HUB throughput and time-to-therapy, omnichannel KPIs; HCP/HCO master and territory/account alignment, payer access insights.
- Target state:
- Cloud lakehouse with curated data products, governed zones (raw/curated/semantics), centralized catalog/lineage, and privacy/security services.
- FAIR/semantic layer with ontologies aligned to standards; API-first interoperability (FHIR, IDMP, REST/GraphQL).
- GxP validation scope and risk control matrix; segregation of GxP vs. non-GxP workloads; DevSecOps and data product lifecycle management.
Workstream 2: Enterprise Data Model, Ontologies, and Glossary
We built a semantic foundation to enable interoperability and analytics.
- Ontology alignment:
- Preclinical: BioPAX/OBI/ChEBI-based entities for pathways, assays, reagents; ISA-Tab structures for experiments; provenance (PROV-O).
- CMC: materials, lots, batches, equipment, process steps (ISA-88/ISA-95 concepts), QC tests/results, stability protocols; controlled vocabularies for deviations/CAPA and failure modes.
- Clinical: CDISC SDTM/ADaM domains; HL7 FHIR resources for eSource interoperability; site/subject/visit/assessment models; coding standards (MedDRA/WHO-DD).
- Commercial: HCP/HCO/provider networks, payer plans/formularies, account hierarchies; product/channel identifiers; GTN dimensions.
- Business glossary and data contracts:
- Canonical definitions (e.g., “lot release lead time,” “enrollment rate,” “first-fill rate,” “time-to-therapy”); critical data elements (CDEs) with owners/stewards.
- Data contracts specifying schemas, semantics, SLAs (latency/quality), and lineage for each data product.
Workstream 3: Master Data and Reference Data Management (MDM/RDM)
We established golden records and reference code sets with stewardship and quality controls.
- Domains and scope:
- Item/Lot/COA; Site/Supplier; Subject/Token; HCP/HCO/Account; Product/SKU; Process/equipment IDs; Payer/Plan; Country/Region/Standards mapping (MedDRA, CDISC, IDMP).
- MDM patterns:
- Consolidation for global HCP/HCO/Account; coexistence for Item/Lot across ERP/LIMS/MES; registry for Subject/Token with privacy services; governance workflows for create/change (SoD, approvals).
- Data quality rules:
- Uniqueness, validity, referential integrity, schema conformance; survivorship and match/merge rules; exception handling and stewardship queues.
Workstream 4: Platform Architecture and Integration
We designed and implemented a validated, cloud-native data platform with secure, scalable integrations.
- Architecture:
- Lakehouse (object storage + SQL query engine) with medallion layers (raw/clean/semantic/data products); metadata catalog (technical + business), lineage graph, and data observability tooling.
- API/messaging: event-driven ingestion where feasible; REST/GraphQL APIs; FHIR for clinical interoperability; batch connectors for ELN/LIMS/MES/eBR, CTMS/EDC/eTMF/IRT, ERP/CRM/HUB/SP/SD, historian (process data).
- Security and privacy:
- RBAC/ABAC; data masking, tokenization, de-identification/pseudonymization; encryption at rest/in transit; secrets management; audit logging.
- Operationalization:
- Data pipelines with CI/CD; data contracts and schema evolution; data quality monitors; SLO dashboards; backup/restore and disaster recovery procedures.
Workstream 5: CSV/CSA, Part 11/Annex 11 Controls, and Data Integrity
We embedded risk-based validation and data integrity controls suitable for GxP workloads.
- Validation strategy:
- Risk assessment for each data product/pipeline; define GxP-relevance; adopt CSA (Computer Software Assurance) principles to focus on critical functionality; supply IQ/OQ/PQ as appropriate.
- Controls:
- Electronic records/signature (Part 11); user access/SoD; audit trails (non-repudiation, timestamp sync); change control; backup/restore testing; data retention and archival.
- ALCOA+:
- Attributable, Legible, Contemporaneous, Original, Accurate plus Complete, Consistent, Enduring, and Available reflected in pipeline design and metadata capture.
Workstream 6: Privacy, Tokenization, and Consent Management
We implemented privacy-by-design for clinical, safety, and patient-support data.
- De-identification and tokenization:
- Privacy safe linking across clinical domains and real-world data; token services; reversible tokens where permitted with key escrow; irreversible pseudonymization for analytics.
- Consent and provenance:
- Consent status tracking; purpose limitation; data subject rights workflows (access, deletion); provenance metadata for dataset origination and transformations.
- Policies:
- HIPAA/GDPR guidance; data minimization; cross-border data transfer; vendor DPAs; privacy impact assessments (PIAs).
Workstream 7: Analytics Enablement, ML Ops, and Model Governance
We enabled analytics safely and reproducibly across domains.
- Reusable analytics layer:
- Curated data products; semantic SQL; feature store with lineage; notebook environments with governed access; BI dashboards.
- MLOps:
- Versioned models/data; experiment tracking; model registry; bias/fairness checks; drift monitoring; model risk classification (GxP vs. non-GxP) and validation plans for high-risk use cases.
- Validated analytics:
- For GxP analytics (e.g., release decision support), define acceptance criteria, verification/validation, and change control; for exploratory analytics, use fit-for-purpose safeguards.
Workstream 8: Governance Operating Model and Stewardship
We established decision-making and accountability mechanisms.
- Data council:
- Cross-functional body to approve standards, ontologies, data contracts, and priorities; resolve ownership disputes; approve exceptions.
- Stewardship:
- Domain stewards for Preclinical, CMC, Clinical, Safety, Commercial; responsibilities for data quality, glossary, and issue triage; KPIs and incentives.
- Policies and SOPs:
- Data classification and handling; data lifecycle; DQ incident management; catalog and access request; change management for schemas/ontologies.
Workstream 9: Roadmap, Change Management, and Adoption
We delivered phased value while building sustainable capabilities.
- Roadmap:
- 12–18 month plan with quick wins (e.g., lot genealogy MVP, SDTM harmonization, HCP/HCO MDM) and subsequent expansions (stability analytics, HUB-to-EDC tokenization).
- Change management:
- Training for scientists, QA, Clinical Ops, Biostats, and Commercial Analytics; office hours; champions network; communications on “why/what/how.”
- Adoption KPIs:
- Catalog coverage, dataset reuse, reduction in reconciliation time, DQ incident closure time, inspection observations avoided, analytics cycle-time reduction.
Workstream 10: Partner and Ecosystem Integration
We aligned external data flows with internal standards and controls.
- CDMO/CRO/SP/SD onboarding:
- Data exchange standards (SFTP/API, schema, QC checks), SLAs, and onboarding playbooks; encryption, identity, and audit requirements.
- Alliance alignment:
- Data rights and use; IP/ownership; joint governance touchpoints; data quality expectations captured in agreements.
4) Data Request
We requested datasets and documents required to execute Biotech Data Platform And Governance across Emerging Therapeutic, Clinical-Stage, Commercial Biotech, Platform Biotech, and Biotech Investors & Incubators. Typical horizons: 24–36 months historical where feasible; near-real-time feeds for operational datasets.
- Preclinical/Discovery:
- ELN exports (assays, results, protocols), instrument data (omics, imaging), plate maps, sample metadata, reagent inventories; ontology references and legacy code lists.
- CMC/Tech Ops:
- LIMS test plans and results, COAs; MES/eBR batch records (materials, steps, parameters), deviations/CAPA, change controls; historian (process/time-series); stability protocols/results; QC/QA training and approval logs.
- Clinical/Safety:
- CTMS site/visit calendars; EDC data with audit trails; eTMF metadata; IRT randomization/treatment; PV case management (ICSRs), safety signals; coding dictionaries (MedDRA/WHO-DD); SDTM/ADaM packages.
- Commercial/Access:
- CRM entities (HCP/HCO/Accounts); HUB BV/PA/appeals events; SP/SD dispenses; payer/plan formularies; GTN (chargebacks, rebates, returns); omnichannel engagement logs.
- Enterprise Systems:
- ERP (items, lots, suppliers, inventory); HRIS (roles, org); ticketing/change management; identity/access logs; data catalog (if any); current data lake/warehouse schemas.
- Governance & Compliance:
- Part 11/Annex 11 validation status; CSV/CSA documentation; SOPs for data handling; privacy policies and PIAs; data sharing agreements; vendor DPAs/BAAs.
- Reference/Standards:
- CDISC SDTM/ADaM standards; HL7 FHIR, IDMP mappings; OBO/BioPAX ontology preferences; code sets (units, analytes, lab tests, adverse events).
Common data quality pitfalls included: inconsistent identifiers across systems (lot, subject, HCP/HCO), missing or uncontrolled vocabularies, weak audit trails on legacy transformations, orphaned datasets without provenance, free-text fields for controlled concepts, delayed partner data, and privacy risk from inadequately de-identified clinical data. We established a data dictionary, ID strategy, stewardship owners, and validation/QA routines prior to integrations.
5) Questions for Client
- Which business decisions and inspections must the platform enable in the next 6–12 months (e.g., PPQ/launch readiness, pivotal data cut, payer interactions)?
- What are the top three cross-domain analytics you need (e.g., lot genealogy to stability to complaint; enrollment-to-supply coordination; HUB-to-EDC patient progression)?
- Which datasets and systems are in-scope for GxP validation vs. fit-for-purpose controls; what is your risk tolerance and CSV/CSA approach?
- What ontology and standards preferences exist (CDISC, BioPAX/OBO, FHIR, IDMP); where is alignment with partners imperative?
- What master data domains are most problematic (e.g., Lot/COA, Subject/Token, HCP/HCO/Account); who should steward them?
- What privacy models (tokenization, de-identification) and consent constraints apply; where are cross-border data transfers expected?
- Which quick wins would drive adoption (e.g., lot genealogy dashboard; SDTM harmonization; HCP/HCO MDM for account planning)?
- What is the preferred cloud and tool stack; what enterprise security and networking controls must be satisfied?
- How should we govern data products and changes (council cadence, data contracts, exceptions); what KPIs will indicate success?
- Which external partners (CDMO/CRO/SP/SD) must onboard to the platform within the first quarter?
6) Interview Guide for Subject Matter Experts
Head of R&D Informatics / Discovery IT
- Which preclinical datasets and instruments are highest value; where do standards and metadata break down?
- How do you trace assay provenance and results; what ontology support is needed?
- What FAIR improvements would reduce rework and speed experiment reuse?
Head of CMC / Tech Ops Digital
- Where does lot genealogy fail today; how do deviations/CAPAs use data from MES/LIMS/historian?
- Which batch parameters and QC tests are critical to link for yield/quality insights?
- What validation posture is required for CMC analytics and release decision support?
Quality / CSV / Compliance Lead
- What are the highest priority Part 11/Annex 11 risks in current data flows; where do audit trails and e-signatures need strengthening?
- How should we scope CSA and risk-based validation for the platform and pipelines?
- Which SOPs and training must change to support the new operating model?
Clinical Data Management / Biostatistics
- Where do SDTM/ADaM packages face friction; which EDC/CTMS/eTMF linkages are most fragile?
- How should tokenization and FHIR support eSource or decentralized trial data collection?
- What turnaround times and quality thresholds are required for interim analyses?
Pharmacovigilance / Safety
- How do you ingest ICSR and safety signals; what coding/medication mappings are needed?
- Where do safety and clinical datasets need reconciled views; what privacy constraints apply?
Commercial Analytics / CRM Owner
- What HCP/HCO/Account master issues impede targeting and KAM planning; which feeds (SP/SD/HUB) are most variable?
- Which GTN, HUB, and time-to-therapy metrics must be standardized; how should we manage data rights with partners?
Security / Privacy Officer
- What RBAC/ABAC policies, encryption standards, and logging must be enforced; how do we handle cross-border data?
- What tokenization/de-identification standards and consent models are acceptable?
Regulatory Affairs / Data Standards
- Which standards (CDISC, IDMP) and data lineage evidence are expected in submissions and inspections?
- How should we document comparability and stability analytics within the platform?
IT / Enterprise Architecture
- What cloud, networking, and identity prerequisites must the platform satisfy; where are integration bottlenecks?
- What catalog/lineage tooling and data product lifecycle management do you prefer?
7) Timeline
We executed a 12–14 week plan tailored to Biotech Data Platform And Governance within AI, Data & Analytics.
- Weeks 1–2: Diagnostic and Target-State Blueprint
- Interviewed stakeholders; inventoried systems and datasets; assessed data integrity/validation risks; defined priority use cases; drafted target architecture and validation scope.
- Decision Gate A: Approved use cases, ontology standards, validation strategy (CSV/CSA), privacy posture, and initial MDM domains.
- Weeks 3–4: Enterprise Data Model, Ontologies, and Glossary
- Authored semantic models and business glossary; mapped standards (CDISC, BioPAX/OBO, FHIR, IDMP) to internal concepts; defined data contracts and CDEs.
- Decision Gate B: Ratified ontology choices and glossary; assigned stewards for critical domains.
- Weeks 5–6: MDM/RDM and Data Quality Foundation
- Implemented MDM for first domains (e.g., Item/Lot, HCP/HCO/Account); configured match/merge and DQ rules; established stewardship workflows and dashboards.
- Decision Gate C: Approved golden record rules and DQ thresholds; greenlit partner onboarding approach.
- Weeks 7–8: Platform Build and Integrations (MVP)
- Deployed lakehouse, catalog, lineage, and security controls; built pipelines for initial systems (e.g., LIMS↔MES↔ERP lot genealogy; EDC↔CTMS SDTM harmonization); implemented tokenization service.
- Decision Gate D: Validated MVP pipelines; confirmed audit trails, access, and privacy controls; agreed CSV/CSA evidence for GxP pipelines.
- Weeks 9–10: Analytics Layer and Governance Operating Model
- Delivered curated data products and dashboards (e.g., lot genealogy/stability; enrollment/site performance; HUB time-to-therapy); launched data council and stewardship cadences; published policies/SOPs.
- Decision Gate E: Accepted analytics MVPs; confirmed governance cadence and KPI suite (catalog coverage, DQ incident closure).
- Weeks 11–12: Partner Onboarding, Validation Pack, and Handoff
- Onboarded 1–2 external partners (CDMO/CRO/SP) to standard interfaces; completed validation documentation (risk assessment, IQ/OQ/PQ or CSA evidence); trained teams; finalized roadmap (90–180 days).
- Decision Gate F: Approved go-live; scheduled quarterly refresh of ontologies/MDM and platform expansions.
- Weeks 13–14 (optional): Stabilization and Scale
- Monitored DQ and lineage alerts; tuned data contracts; expanded MDM domains; added additional pipelines (e.g., PV ICSR feeds, historian features); executed change management and adoption support.
Critical path items included ontology alignment across functions, validation scope decisions, privacy/tokenization design, partner data onboarding readiness, and identity/access integration with enterprise security.
8) Deliverables
- Target-State Architecture and Validation Strategy
- Reference architecture for lakehouse, catalog, lineage, security; CSV/CSA risk matrix and validation plan; Part 11/Annex 11 control design.
- Enterprise Data Model, Ontologies, and Business Glossary
- Semantic models across preclinical/CMC/clinical/commercial; standards mappings (CDISC, BioPAX/OBO, FHIR, IDMP); data contracts; CDE dictionary.
- MDM/RDM Blueprint and Configuration
- Golden record models for Item/Lot, Subject/Token, HCP/HCO/Account; match/merge rules; stewardship workflows; DQ rules and dashboards.
- Platform Build (MVP) and Integration Playbooks
- Deployed lakehouse, catalog, and lineage; secure pipelines for initial systems; partner onboarding standards (schemas, QC checks, SLAs); privacy/tokenization services.
- Data Integrity and Validation Pack
- Risk assessments; IQ/OQ/PQ or CSA evidence; audit trail and access control verification; backup/restore tests; SOPs for change control and incident management.
- Analytics and Dashboard Suite
- Lot genealogy and stability trending; deviation/cycle-time KPIs; enrollment and site performance; HUB time-to-therapy; GTN/omnichannel harmonization (where in scope).
- Governance Operating Model
- Data council charter; stewardship RACI; policies for data classification, lifecycle, data quality, access; catalog usage guide and access workflows.
- Privacy and Security Controls
- Tokenization/de-identification frameworks; consent/provenance capture; RBAC/ABAC policies; logging/monitoring runbooks.
- Partner/Ecosystem Integration Kit
- Data exchange standards; onboarding checklist; data rights and quality expectations; sample contracts/DPAs and technical templates.
- Change Management and Training Materials
- Role-based training for scientists, QA/CSV, Clinical Ops, Biostats, Commercial; communications plan; adoption KPIs and success measures.
- Roadmap and Investment Case
- 12–18 month expansion plan, TCO/benefit narrative, staffing model, and sequencing across additional domains and partners.
9) Industry Insights
- FAIR and semantics are essential in multi-modal pipelines
- From target discovery to real-world evidence, harmonized ontologies and FAIR metadata reduce rework, enable cross-study analysis, and accelerate submissions; standards (CDISC, FHIR, IDMP, BioPAX/OBO) are now table stakes with partners and regulators.
- Data integrity scrutiny is rising
- Inspections increasingly probe data lineage across CMC and clinical domains; ALCOA+ expectations extend into analytics pipelines; risk-based CSA accelerates validation without sacrificing control.
- Cloud lakehouse with a strong catalog/lineage is the pragmatic path
- Hybrid data products—curated, governed, and discoverable—beat monolithic warehouses for scientific and operational agility; success depends on data contracts, DQ observability, and CI/CD for pipelines.
- Privacy-by-design unlocks clinical and commercial convergence
- Tokenization and consent-aware data products enable linking HUB/EMR/claims with clinical data while preserving privacy; consistent policy is vital for multi-country programs.
- Data mesh concepts require governance maturity
- Domain-oriented data products work when stewards, standards, and contracts are enforced; without governance, mesh devolves to chaos—especially in GxP contexts.
- Validated analytics is achievable with model risk governance
- Classify models by risk, enforce versioning and testing, and document acceptance criteria; apply full validation to high-impact use cases (e.g., release decision support), and fit-for-purpose controls elsewhere.
- What “good” looks like
- Enterprise glossary and ontologies mapped to standards; MDM across core domains; lakehouse with catalog, lineage, and privacy services; risk-based validation; governed data products powering cross-domain analytics; dashboards with trusted KPIs; data council and stewardship with measurable DQ improvements.
- Near-term watch points
- Evolving guidance on CSA and AI governance; IDMP/FHIR adoption timelines with regulators and partners; CDMO/CRO data quality variability; vendor consolidation and integration lifecycles; privacy regulation changes (cross-border transfers). Quarterly refreshes of standards, policies, and roadmaps keep the platform resilient.
Implications for clients we served included enabling Emerging Therapeutic Biotech to lay a right-sized, FAIR/GxP-compliant foundation before IND/IMPD; supporting Clinical-Stage Biotech in harmonizing SDTM/ADaM and lot genealogy for pivotal and PPQ readiness; equipping Commercial Biotech with privacy-safe integration of HUB/SP/SD and CRM/GTN data; guiding Platform Biotech to standardize ontologies, MDM, and data products across partnered programs; and providing Biotech Investors & Incubators with diligence lenses on data integrity, interoperability, and analytics readiness across portfolio companies.
